By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Otsuka Pharmaceutical Co., Ltd. 

2-9 Kanda Tsukasa-cho
Chiyoda-ku
Tokyo    101-8535  Japan
Phone: 03-3292-0021 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Otsuka Pharma Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment To Medimetriks Pharmaceuticals, Inc. 2/9/2016 5:54:19 AM
Ariad (ARIA) And Otsuka Pharma Submit New Drug Application In Japan For Ponatinib 1/8/2016 12:01:17 PM
U.S. FDA Accepts First Digital Medicine New Drug Application For Otsuka Pharma And Proteus Digital Health, Inc. 9/10/2015 10:17:19 AM
Efficacy Results Of Otsuka Pharma’s Delamanid (Deltyba) For Extensively Drug-Resistant Tuberculosis (XDR-TB) Published In The New England Journal of Medicine 7/16/2015 11:12:48 AM
Otsuka Pharma, H. Lundbeck A/S (LUN.CO) Beat Competitors With FDA Approval of Schizophrenia Drug 7/13/2015 6:38:10 AM
Otsuka Pharmaceutical Co., Ltd.’s JINARC The First-Ever Treatment Approved In Europe For Adults Living With ADPKD, A Chronic Genetic Kidney Disease 5/27/2015 10:57:58 AM
Otsuka Pharmaceutical Co., Ltd. Release: Pre-Filled Dual-Chamber Syringe For Abilify Maintena (Aripiprazole) Prolonged-Release Suspension For Injection, Used In The Treatment Of Schizophrenia, Receives Positive CHMP Opinion (Approval In EU) 3/30/2015 12:59:23 PM
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 3/2/2015 6:59:19 AM
Otsuka Pharmaceutical Co., Ltd. Release: CHMP Recommends Jinarc (Tolvaptan) For Approval In EU: The First Pharmaceutical Treatment For Autosomal Dominant Polycystic Kidney Disease (Adpkd) 2/27/2015 8:22:32 AM
Otsuka Pharmaceutical Co., Ltd. Release: First-Ever Treatment Approved In Canada For Adults Living With ADPKD, A Life-Threatening Kidney Disease 2/27/2015 6:47:35 AM
12345678910...
//-->